Late toxicities and clinical outcome at 5  years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

ConclusionsThe CAPOX50 regimen did not improve local control, disease-free survival and overall survival in the ACCORD12 trial. Late toxicities did not differ between treatment arms.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research